99

  • O'qishlar soni 99
  • Nashr sanasi 05-01-2024
  • Asosiy tilO'zbek
  • Sahifalar168-187
Kalit so'z
Русский

Европейская академия отологии и нейротологии в сотрудничестве с Японским отологическим обществом (EAONO/JOS) недавно выпустили совместный консенсусный документ. В этом документе изложены определения, классификация и стадирование холестеатомы среднего уха. Основными целями были создание стандартной терминологии для описания холестеатомы, разделение ее на отдельные группы для облегчения сравнения результатов хирургического лечения и создание системы стадирования, отражающей степень тяжести, сложность удаления и восстановления нормальной функции.

№ Muallifning F.I.Sh. Lavozimi Tashkilot nomi
1 Erkinov O.. г.Ташкент Alfraganus university
№ Havola nomi
1 Yung M, Tono T, Olszewska E, et al. EAONO/JOS Joint consensus statements on the definitions, classification and staging of middle ear cholesteatoma. J Int Adv Otol. 2017;13:1–8. doi: 10.5152/iao.2017.3363. Müller J. Ueber den feineren bau und die formen der krankhaften geschwulste. Berlin, G Reimer. 1838. Folio. De Verney JG. Traité de l’organie de l’ouïe. Paris: E. Michallet; 1683. Aquino JE, Cruz Filho NA, de Aquino JN. Epidemiology of middle ear and mastoid cholesteatomas: study of 1146 cases. Braz J Otorhinolaryngol. 2011;77:341–347. doi: 10.1590/S1808-86942011000300012 Bennett M, Warren F, Jackson GC. Congenital cholesteatoma: theories, facts and 53 patients. Otolaryngol Clin N Am. 2006;39:1081–1094. doi: 10.1016/j.otc.2006.08.001 Shohet JA, De Jong AI. The management of pediatric cholesteatoms. Otolaryngol Clin N Am. 2002;35:841–851. doi: 10.1016/S0030-6665(02)00052-X. Olszewska E, Wagner M, Bernal-Sprekelsen M, et al. Etiopathogenesis of cholesteatoma. Eur Arch Otorhinolaryngol. 2004;261:6–24. doi: 10.1007/s00405-003-0623-x Barath K, Huber AM, Stampfil P, et al. Neuroradiology of cholesteatomas. AJNR Am J Neuroradiol. 2011;32:221–229. doi: 10.3174/ajnr.A2052 Jennings BA, Prinsley P, Philpott C, et al. The genetics of cholesteatoma. A systematic review using narrative synthesis. Clin Otolaryngol. 2017;43:55–67. doi: 10.1111/coa.12900. Bois E, Nassar M, Zenaty D, et al. Otologic disorders in Turner syndrome. Eur Ann Otorhinolaryngol Head Neck Dis. 2017;135:21–24. doi: 10.1016/j.anorl.2017.08.006 Lim DBN, Gault EJ, Kubba H, et al. Cholesteatoma has a high prevalence in Turner syndrome, highlighting the need for earlier diagnosis and the potential benefits of otoscopy training for paediatricians. Acta Paediatr. 2014;103:e282–e287. doi: 10.1111/apa.12450 Hall JE, Richter GT, Choo DI. Surgical management of otologic disease in pediatric patients with Turner syndrome. Int J Pediatr Otorhinolaryngol. 2009;73:57–65. doi: 10.1016/j.ijporl.2008.09.022 Mann W, Al-Nawas B, Wriedt S. Cholesteatoma of the hypotympanum in a patient with Treacher Collins syndrome. Auris Nasus Larynx. 2014;41:101–104. doi: 10.1016/j.anl.2013.05.005. Nash R, Possamai V, Maskell S, et al. Canal wall reconstruction and preservation in the surgical management of cholesteatoma in children with Down’s syndrome. Int J Pediatr Otorhinolaryngol. 2014;78:1747–1751. doi: 10.1016/j.ijporl.2014.07.038 Paulson LM, Weaver TS, Macarthur CJ. Outcomes of tympanostomy tube placement in children with Down syndrome—a retrospective review. Int J Pediatr Otorhinolaryngol. 2014;78:223–226. doi: 10.1016/j.ijporl.2013.10.062. Bacciu A, Pasanisi E, Vincenti V, et al. Surgical treatment of middle ear cholesteatoma in children with Down syndrome. Otol Neurotol. 2005;26:1007–1010. doi: 10.1097/01.mao.0000185042.46523.9b. Suzuki C, Ohtani I. Bone destruction resulting from rupture of a cholesteatoma sac: temporal bone pathology. Otol Neurotol. 2004;25:674–677. doi: 10.1097/00129492-200409000-00005. Büchner SA, Itin P. Focal dermal hypoplasia syndrome in a male patient. Report of a case and histologic and immunohistochemical studies. Arch Dermatol. 1992;128:1078–1082. doi: 10.1001/archderm.1992.01680180072008. Imbery TE, Sobin LB, Commesso E, et al. Long-term otologic and audiometric outcomes in patients with cleft palate. Otolaryngol Head Neck Surg. 2017;157:676–682. doi: 10.1177/0194599817707514 Kopcsányi G, Vincze O, Bagdán V, et al. Retrospective analysis of tympanoplasty in children with cleft palate: a 24-year experience. II. Cholesteatomatous cases. Int J Pediatr Otorhinolaryngol. 2015;79:698–706. doi: 10.1016/j.ijporl.2015.02.020. Djurhuus BD, Skytthe A, Faber CE, Christensen K. Cholesteatoma risk in 8,593 orofacial cleft cases and 6,989 siblings: a nationwide study. Laryngoscope. 2015;125:1225–1229. doi: 10.1002/lary.25022 Lau CC, Loh KK, Kunaratnam N. Middle ear diseases in cleft palate patients in Singapore. Ann Acad Med Singap. 1988;17:372–374 Kuo CL, Lien CF, Chu CH, et al. Otitis media with effusion in children with cleft lip and palate: a narrative review. Int J Pediatr Otorhinolaryngol. 2013;77:1403–1409. doi: 10.1016/j.ijporl.2013.07.015. James AL, Papsin BC. Some considerations in congenital cholesteatoma. Curr Opin Otolaryngol Head Neck Surg. 2013;21:431–439. doi: 10.1097/MOO.0b013e328364b457 Harris L, Cushing SL, Hubbard B, et al. Impact of cleft palate type on the incidence of acquired cholesteatoma. Int J Pediatr Otorhinolaryngol. 2013;77:695–698. doi: 10.1016/j.ijporl.2013.01.020 Kuo CL, Shiao AS, Wen HC, et al. Increased risk of cholesteatoma among patients with allergic rhinitis: a nationwide investigation. Laryngoscope. 2017;128:547–553. doi: 10.1002/lary.26220. Kuo CL, Shiao AS, Yung M, et al. Updates and knowledge gaps in cholesteatoma research. Biomed Res Int. 2015;2015:1–17. Michaels L. Origin of congenital cholesteatoma from a normally occurring epidermoid rest in the developing middle ear. Int J Pediatr Otorhinolaryngol. 1988;15:51–65. doi: 10.1016/0165-5876(88)90050-X. Levenson MJ, Michaels L, Parisier SC, et al. Congenital cholesteatomas in children: an embryologic correlation. Laryngoscope. 1988;98:949–955. doi: 10.1288/00005537-198809000-00008. Aimi K. Role of the tympanic ring in the pathogenesis of congenital cholesteatoma. Laryngoscope. 1983;93:1140–1146. doi: 10.1288/00005537-198309000-00005 Tos M. A new pathogenesis of mesotympanic (congenital) cholesteatoma. Laryngoscope. 2000;110:1890–1897. doi: 10.1097/00005537-200011000-00023. Kuo CL. Etiopathogenesis of acquired cholesteatoma: prominent theories and recent advances in biomolecular research. Laryngoscope. 2015;125:234–240. doi: 10.1002/lary.24890 Sudhoff H, Tos M. Pathogenesis of attic cholesteatoma: clinical and immunohistochemical support for combination of retraction theory and proliferation theory. Am J Otol. 2000;21:786–792. Karmody CS, Northrop C. The pathogenesis of acquired cholesteatoma of the human middle ear: support for the migration hypothesis. Otol Neurotol. 2012;33:42–47. doi: 10.1097/MAO.0b013e31823c919c. Falcioni M, Taibah A, Rohit Pulsatile tinnitus as a rare presenting symptom of residual cholesteatoma. J Laryngol Otol. 2004;118:165–166. doi: 10.1258/002221504772784694 Ahn JM, Huang CC, Abramson M. Localization of interleukin-1 in human cholesteatoma. Am J Otolaryngol. 1990;11:71–77. doi: 10.1016/0196-0709(90)90001-C. Venail F, Bonafe A, Poirrier V, et al. Comparison of echo-planar diffusion-weighted imaging and delayed postcontrast T1-weighted MR imaging for the detection of residual cholesteatoma. AJNR Am J Neuroradiol. 2008;29:1363–1368. doi: 10.3174/ajnr.A1100. Corrales CE, Blevins NH. Imaging for evaluation of cholesteatoma: current concepts and future directions. Curr Opin Otolaryngol Head Neck Surg. 2013;21:461–467. doi: 10.1097/MOO.0b013e328364b473. Henninger B, Kremser C. Diffusion weighted imaging for the detection and evaluation of cholesteatoma. World J Radiol. 2017;28:217–222. doi: 10.4329/wjr.v9.i5.217 Vercruysse JP, De Foer B, Pouillon M, et al. The value of diffusion-weighted MR imaging in the diagnosis of primary acquired and residual cholesteatoma: a surgical verified study of 100 patients. Eur Radiol. 2006;16:1461–1467. doi: 10.1007/s00330-006-0160-2. Más-Estellés F, Mateos-Fernández M, Carrascosa-Bisquert B, et al. Contemporary non-echo-planar diffusion-weighted imaging of middle ear cholesteatomas. Radiographics. 2012;32:1197–1213. doi: 10.1148/rg.324115109. Caponetti G, Thompson LD, Pantanowitz L. Cholesteatoma. Ear Nose Throat J. 2009;88:1196–1198. Bassiouny M, Badour N, Omran A, et al. Histopathological and immunohistochemical characteristics of acquired cholesteatoma in children and adults. EJENTAS. 2012;13:7–12. Rothschild S, Ciernik IF, Hartmann M, et al. Cholesteatoma triggering squamous cell carcinoma: case report and literature review of a rare tumor. Am J Otolaryngol. 2009;30:256–260. doi: 10.1016/j.amjoto.2008.06.011. Hamed MA, Nakata S, Shiogama K, et al. Cytokeratin 13, Cytokeratin 17, and Ki-67 expression in human acquired cholesteatoma and their correlation with its destructive capacity. Clin Exp Otorhinolaryngol. 2017;10:213–220. doi: 10.21053/ceo.2016.01263. Chole RA, Tinling SP. Basal lamina breaks in the histogenesis of cholesteatoma. Laryngoscope. 1985;95:270–275. doi: 10.1288/00005537-198503000-00005 Ferlito O, Devaney KO, Rinaldo A, et al. Clinicopathological consultation ear cholesteatoma versus cholesterol granuloma. Ann Otol Rhinol Laryngol. 1997;106:79–85. doi: 10.1177/000348949710600114 Preciado DA. Biology of cholesteatoma: special considerations in pediatric patients. Int J Pediatr Otorhinolaryngol. 2012;76:319–321. doi: 10.1016/j.ijporl.2011.12.014. Maniu A, Harabagiu O, Perde Schrepler M, et al. Molecular biology of cholesteatoma. Rom J Morphol Embryol. 2014;55:7–13. Sudhoff H, Dazert S, Gonzales AM, et al. Angiogenesis and angiogenic growth factors in middle ear cholesteatoma. Am J Otol. 2000;21:793–798. Fukudome S, Wang C, Hamajima Y, et al. Regulation of the angiogenesis of acquired middle ear cholesteatomas by inhibitor of DNA binding transcription factor. JAMA Otolaryngol Head Neck Surg. 2013;139:273–278. doi: 10.1001/jamaoto.2013.1750 Haruyama T, Furukawa M, Kusunoki T, et al. Expression of IL-17 and its role in bone destruction in human middle ear cholesteatoma. J Otorhinolaryngol Relat Spec. 2010;72:325–331. doi: 10.1159/000319897. Olszewska E, Matulka M, Mroczko B, et al. Diagnostic value of matrix metalloproteinase 9 and tissue inhibitor of matrix metalloproteinases 1 in cholesteatoma. Histol Histopathol. 2016;31:307–315. Chen AP, Wang B, Zhong F, et al. Expression levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin are associated with middle ear cholesteatoma risk. Acta Otolaryngol. 2015;135:655–666. doi: 10.3109/00016489.2015.1011789. Kuo CL, Liao WH, Shiao AS. A review of current progress in acquired cholesteatoma management. Eur Arch Otorhinolaryngol. 2015;272:3601–3609. doi: 10.1007/s00405-014-3291-0. Morita Y, Takahashi K, Izumi S, et al. Risk factors of recurrence in pediatric congenital cholesteatoma. Otol Neurotol. 2017;38:1463–1469. doi: 10.1097/MAO.0000000000001587 Vital V. Pediatric cholesteatoma: personal experience and review of the literature. Otorhinolaryngol Head Neck Surg. 2011;45:5–14. Zhang H, Wong PY, Magos T, et al. Use of narrow band imaging and 4K technology in otology and neuro-otology: preliminary experience and feasibility study. Eur Arch Otorhinolaryngol. 2017;275:301–305. doi: 10.1007/s00405-017-4783-5. Tomlin J, Chang D, McCutcheon B, et al. Surgical technique and recurrence in cholesteatoma: a meta-analysis. Audiol Neurootol. 2013;18:135–142. doi: 10.1159/000346140.
Kutilmoqda